(Date:12/2/2009)..., JERUSALEM, Israel, December 2 /PRNewswire/...y evaluating the preclinical (animal study) safety...ines technology from Weill,Cornell Medical College...o,treat inherited anemias such as Cooley,s Anemia....technologies to expand, ex vivo,populations of st...
(Date:12/2/2009)..., SINGAPORE, Dec. 2 S*BIO Pte Ltd...ral JAK2 inhibitor, SB1518, at The American Societ... in New Orleans. ,, Data will be presented on t...on trial of SB1518 detailing its safety, tolerabil...ofile in dose levels ranging from 100 to 600 mg. T...
(Date:12/2/2009)... RESTON, Va., Dec. 2 /PRNewswire-Asia-FirstCall...Company") (OTC Bulletin Board: EMDY), a leading,pr...rmula, milk powder and,soybean products in China, ...in the Spring issue of US Food & Drink Executi... 250,000 executives in the food and beverage indus...
(Date:12/2/2009)... NANJING, China, Dec. 2 /PRNewswire-Asia/ -- Si...any") (NYSE: SCR ), a leading pharmaceutical com...g, and marketing of branded,generic and proprietar...05 of,its drugs have been included in China,s Nati...ssued by China,s Ministry of Human Resources and S...
Breaking Biology Technology:Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3... LELYSTAD, Netherlands, March 3, Genmab A/S (OTC: ...research collaboration aimed at identifying fully,...sease targets.,Intractable targets include those t...ble technologies but are highly desirable for targ...es can for example be due to the,fact that target ...
...3 Vermillion, Inc.,(Nasdaq: VRML ), a high-value...at it has entered into an exclusive license agreem...cialize a novel biomarker panel used to,assess the...d to affect up,to 12 million Americans, PAD is a s...disease can result in severe complications, includ...
...iMedx, Inc., a development-stage,medical device co...n,appointed President. In this role, Mr. Splan wil...o the MiMedx team., Throughout his 34-year career...ity to manage a wide range of operations and deliv...s. Beginning in 1986, Mr. Splan was,employed by Sm...
Other Biology Technology:Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 2Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 3Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk 2Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk 3MiMedx Announces Brian J. Splan as President 2Mouse Anti-Rat RT1Bu (Class II Polymorphic) Monoclonal Antibody, Biotin Conjugated from AbD Serotec
Mouse Anti-Guinea Pig T-Cells, Pan Monoclonal Antibody, FITC Conjugated from AbD Serotec
Mouse Anti-Rabbit T LYMPHOCYTES Monoclonal Antibody, Unconjugated, Clone KEN-5 from AbD Serotec
Canine Serum from CHEMICON
Biology Products: